In agreement with these studies, our findings showed that STAT1 was upregulated in glioma specimens compared with matched normal tissue specimens, and its high expression was associated with poor OS and DFS in glioma patients, supporting its potential as a reliable prognostic indicator and a promising therapeutic target for glioma. Here, STAT1 is linked to central nervous system cancer.